- ImpediMed (IPD) sees its PREVENT Trial results peer-reviewed and published
- ImpediMed’s study demonstrated intervention in patients with early detection of cancer-related lymphoedema using its L-Dex technology can result in a lower rate of progression to chronic disease, compared to patients with early detection from volume measurements using a tape measure
- The publication concluded that the use of the L-Dex for screening should be a standard approach for prospective breast cancer-related lymphoedema surveillance.
- ImpediMed says this is a significant milestone that will change the trajectory of the company
- ImpediMed last traded at 17.5 cents on January 31
ImpediMed (IPD) has seen its PREVENT Trial results peer-reviewed and published.
The results were published in the journal “Lymphatic Research and Biology,” which is dedicated to the research of lymphatic biology and pathology from biomedical investigators.
ImpediMed’s study demonstrated intervention in patients with early detection of cancer-related lymphoedema using its L-Dex technology resulted in a lower rate of progression to chronic disease, compared to patients with early detection from volume measurements using a tape measure.
The publication concluded that the use of the L-Dex for screening should be a standard approach for prospective breast cancer-related lymphoedema surveillance.
L-Dex is a device that sends a low-level electrical signal through the body. As lymphedema develops, the amount of fluid will increase, making it easier for the signal to travel though the extracellular fluid of the body.
The L-Dex score then compares how easily the electrical signal moves through the limbs. An L-Dex increase of 6.5 or more is an indication that lymphedema is developing, and intervention is needed.
“This timely knowledge gives clinicians the information they need to begin early intervention on their patients at a stage when it’s possible to keep the lymphoedema from advancing,” said Principal Investigator Sheila H. Ridner.
“These findings provide all clinicians addressing lymphoedema in breast cancer patients with clear scientific data regarding the optimal measurement and sound evidence to switch from using tape measurements.”
As part of the study, 1,200 breast cancer patients were screened across thirteen hospitals in the US and Australia over nearly seven years.
The trial met its primary endpoint, with intervention after using the L-Dex resulting in a 7.9 per cent rate of chronic lymphoedema compared to a 19.2 per cent rate of chronic lymphoedema in patients with early detection using tape measure. Early diagnosis of cancer-related lymphoedema using L-Dex and intervention prevented 92 per cent of patients from progressing to chronic lymphoedema.
“Today we reached a significant milestone that will change the trajectory of the company,” ImpediMed Managing Director and CEO Richard Carreon said.
“PREVENT shows to the world that our bioimpedance spectroscopy (BIS) technology can detect medically meaningful fluid shifts in the body.”
ImpediMed last traded at 17.5 cents on January 31.